US equities |
SPCX $168.37 ▲+5.92% NVDA $237.16 ▲+1.37% MU $1,066.56 ▼-0.77% TSLA $378.92 ▲+2.25% MSFT $525.68 ▲+1.57% SNDK $1,714.32 ▼-0.33% INTC $117.22 ▼-1.77% META $743.33 ▲+2.09%
FinancialContent

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

2.335 -0.045 (-1.89%)
Delayed Quote Updated: 1:17 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's after hours session ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's pre-market session ↗
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Host Investor Event
KCC2 Download Day on Wednesday, November 13, 2024 
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics to Present at Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
OVID stock results show that Ovid Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >